Although our OLE data is quite positive our trial was a P2/3. I believe that the FDA will require a full blown phase 3 to issue an approval which tacks on 3 years before any approval. Given that millions of scrips could be written the FDA will want a confirming trial. And that (plus EMA decline) is why shares are $4. BTW, I don't believe any BP partner is forthcoming any time soon unless approved on appeal.
Market Data 
Markets 
AI
